Effectiveness of a clinical pathway for inpatient asthma management

Kevin B. Johnson, Carol J. Blaisdell, Allen Walker, Peyton Eggleston

Research output: Contribution to journalArticle

Abstract

Background. Clinical pathways for asthma are tools that have the potential to improve compliance with nationally recognized management guidelines, but their effect on patient outcomes has not been documented. Objectives. To determine the effect of an asthma clinical pathway on patients length of stay, use of nebulized β-agonist therapy while hospitalized, and use of acute care clinics for 2 weeks after discharge. Design/Methods. The study was a randomized, controlled trial. Patients between the ages of 2 and 18 years admired with an asthma exacerbation and not under the care of an asthma specialist were eligible for the study. Patients were randomized either to a conventional ward (control group) or to a ward using the clinical pathway (intervention group). For 2 weeks after discharge, we collected data to determine whether patients visited a health care provider for worsening asthma. Results. One hundred ten patients (26%) were enrolled. Control and intervention groups had similar demographic and asthma severity profiles. The intervention group had an average length of stay 13 hours shorter than did the control group. In addition, at every dosing interval, the intervention group received less nebulized β-agonist therapy. There were no deaths in either group. Conclusion. A clinical pathway for inpatient asthma decreased the length of stay and β-agonist medication use with no adverse outcomes or increased acute-care encounters through 2 weeks after discharge.

Original languageEnglish (US)
Pages (from-to)1006-1012
Number of pages7
JournalPediatrics
Volume106
Issue number5 I
StatePublished - 2000

Fingerprint

Critical Pathways
Inpatients
Asthma
Length of Stay
Control Groups
Health Personnel
Randomized Controlled Trials
Demography
Guidelines
Therapeutics

Keywords

  • Asthma
  • Clinical pathways
  • Clinical practice guidelines
  • Health services research

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Johnson, K. B., Blaisdell, C. J., Walker, A., & Eggleston, P. (2000). Effectiveness of a clinical pathway for inpatient asthma management. Pediatrics, 106(5 I), 1006-1012.

Effectiveness of a clinical pathway for inpatient asthma management. / Johnson, Kevin B.; Blaisdell, Carol J.; Walker, Allen; Eggleston, Peyton.

In: Pediatrics, Vol. 106, No. 5 I, 2000, p. 1006-1012.

Research output: Contribution to journalArticle

Johnson, KB, Blaisdell, CJ, Walker, A & Eggleston, P 2000, 'Effectiveness of a clinical pathway for inpatient asthma management', Pediatrics, vol. 106, no. 5 I, pp. 1006-1012.
Johnson KB, Blaisdell CJ, Walker A, Eggleston P. Effectiveness of a clinical pathway for inpatient asthma management. Pediatrics. 2000;106(5 I):1006-1012.
Johnson, Kevin B. ; Blaisdell, Carol J. ; Walker, Allen ; Eggleston, Peyton. / Effectiveness of a clinical pathway for inpatient asthma management. In: Pediatrics. 2000 ; Vol. 106, No. 5 I. pp. 1006-1012.
@article{af643e9037b64f908ab6e9edbe62c0b5,
title = "Effectiveness of a clinical pathway for inpatient asthma management",
abstract = "Background. Clinical pathways for asthma are tools that have the potential to improve compliance with nationally recognized management guidelines, but their effect on patient outcomes has not been documented. Objectives. To determine the effect of an asthma clinical pathway on patients length of stay, use of nebulized β-agonist therapy while hospitalized, and use of acute care clinics for 2 weeks after discharge. Design/Methods. The study was a randomized, controlled trial. Patients between the ages of 2 and 18 years admired with an asthma exacerbation and not under the care of an asthma specialist were eligible for the study. Patients were randomized either to a conventional ward (control group) or to a ward using the clinical pathway (intervention group). For 2 weeks after discharge, we collected data to determine whether patients visited a health care provider for worsening asthma. Results. One hundred ten patients (26{\%}) were enrolled. Control and intervention groups had similar demographic and asthma severity profiles. The intervention group had an average length of stay 13 hours shorter than did the control group. In addition, at every dosing interval, the intervention group received less nebulized β-agonist therapy. There were no deaths in either group. Conclusion. A clinical pathway for inpatient asthma decreased the length of stay and β-agonist medication use with no adverse outcomes or increased acute-care encounters through 2 weeks after discharge.",
keywords = "Asthma, Clinical pathways, Clinical practice guidelines, Health services research",
author = "Johnson, {Kevin B.} and Blaisdell, {Carol J.} and Allen Walker and Peyton Eggleston",
year = "2000",
language = "English (US)",
volume = "106",
pages = "1006--1012",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "5 I",

}

TY - JOUR

T1 - Effectiveness of a clinical pathway for inpatient asthma management

AU - Johnson, Kevin B.

AU - Blaisdell, Carol J.

AU - Walker, Allen

AU - Eggleston, Peyton

PY - 2000

Y1 - 2000

N2 - Background. Clinical pathways for asthma are tools that have the potential to improve compliance with nationally recognized management guidelines, but their effect on patient outcomes has not been documented. Objectives. To determine the effect of an asthma clinical pathway on patients length of stay, use of nebulized β-agonist therapy while hospitalized, and use of acute care clinics for 2 weeks after discharge. Design/Methods. The study was a randomized, controlled trial. Patients between the ages of 2 and 18 years admired with an asthma exacerbation and not under the care of an asthma specialist were eligible for the study. Patients were randomized either to a conventional ward (control group) or to a ward using the clinical pathway (intervention group). For 2 weeks after discharge, we collected data to determine whether patients visited a health care provider for worsening asthma. Results. One hundred ten patients (26%) were enrolled. Control and intervention groups had similar demographic and asthma severity profiles. The intervention group had an average length of stay 13 hours shorter than did the control group. In addition, at every dosing interval, the intervention group received less nebulized β-agonist therapy. There were no deaths in either group. Conclusion. A clinical pathway for inpatient asthma decreased the length of stay and β-agonist medication use with no adverse outcomes or increased acute-care encounters through 2 weeks after discharge.

AB - Background. Clinical pathways for asthma are tools that have the potential to improve compliance with nationally recognized management guidelines, but their effect on patient outcomes has not been documented. Objectives. To determine the effect of an asthma clinical pathway on patients length of stay, use of nebulized β-agonist therapy while hospitalized, and use of acute care clinics for 2 weeks after discharge. Design/Methods. The study was a randomized, controlled trial. Patients between the ages of 2 and 18 years admired with an asthma exacerbation and not under the care of an asthma specialist were eligible for the study. Patients were randomized either to a conventional ward (control group) or to a ward using the clinical pathway (intervention group). For 2 weeks after discharge, we collected data to determine whether patients visited a health care provider for worsening asthma. Results. One hundred ten patients (26%) were enrolled. Control and intervention groups had similar demographic and asthma severity profiles. The intervention group had an average length of stay 13 hours shorter than did the control group. In addition, at every dosing interval, the intervention group received less nebulized β-agonist therapy. There were no deaths in either group. Conclusion. A clinical pathway for inpatient asthma decreased the length of stay and β-agonist medication use with no adverse outcomes or increased acute-care encounters through 2 weeks after discharge.

KW - Asthma

KW - Clinical pathways

KW - Clinical practice guidelines

KW - Health services research

UR - http://www.scopus.com/inward/record.url?scp=0033746291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033746291&partnerID=8YFLogxK

M3 - Article

C2 - 11061767

AN - SCOPUS:0033746291

VL - 106

SP - 1006

EP - 1012

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 5 I

ER -